RJA
ATRA icon

Raymond James & Associates’s Atara Biotherapeutics ATRA Stock Holding History

Raymond James & Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-796
Closed -$13.8K – 3967
2024
Q1 		$13.8K Buy
796
+12
+2% +$213 ﹤0.01% 3892
2023
Q4 		$10K Sell
784
-6,802
-90% -$159K ﹤0.01% 3792
2023
Q3 		$281K Buy
7,586
+92
+1% +$4.09K ﹤0.01% 3256
2023
Q2 		$302K Sell
7,494
-62
-0.8% -$3.51K ﹤0.01% 3255
2023
Q1 		$548K Buy
7,556
+287
+4% +$27.8K ﹤0.01% 2868
2022
Q4 		$596K Sell
7,269
-105
-1% -$10.9K ﹤0.01% 2778
2022
Q3 		$697K Buy
7,374
+4,765
+183% +$535K ﹤0.01% 2615
2022
Q2 		$508K Buy
+2,609
New +$426K ﹤0.01% 2907
2020
Q2 		– Sell
-951
Closed -$202K – 3526
2020
Q1 		$202K Buy
951
+104
+12% +$33K ﹤0.01% 3038
2019
Q4 		$349K Buy
847
+38
+5% +$13.1K ﹤0.01% 2985
2019
Q3 		$286K Sell
809
-9
-1% -$3.36K ﹤0.01% 3036
2019
Q2 		$411K Sell
818
-218
-21% -$154K ﹤0.01% 2812
2019
Q1 		$1.03M Buy
1,036
+7
+0.7% +$6.5K ﹤0.01% 2179
2018
Q4 		$893K Sell
1,029
-12
-1% -$11.1K ﹤0.01% 2150
2018
Q3 		$1.08M Sell
1,041
-15
-1% -$14.7K ﹤0.01% 2209
2018
Q2 		$970K Sell
1,056
-61
-5% -$65.5K ﹤0.01% 2240
2018
Q1 		$1.09M Buy
1,117
+104
+10% +$94.8K ﹤0.01% 2076
2017
Q4 		$458K Buy
1,013
+69
+7% +$25.5K ﹤0.01% 2585
2017
Q3 		$391K Hold
944
– – ﹤0.01% 2628
2017
Q2 		$330K Buy
944
+132
+16% +$50.9K ﹤0.01% 2662
2017
Q1 		$417K Buy
812
+91
+13% +$37.7K ﹤0.01% 2495
2016
Q4 		$256K Buy
+721
New +$305K ﹤0.01% 2742

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Raymond James & Associates's ATRA Position: Q2 2024 in Review

Raymond James & Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 796 shares — an estimated $13.8K sold.

Raymond James & Associates first reported a position in ATRA in Q4 2016 and held it in 22 quarters. The position peaked at $1.09M in Q1 2018. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Raymond James & Associates reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 796 Atara Biotherapeutics shares in Q2 2024, an estimated $13.8K.
  • Raymond James & Associates first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 22 quarters.
  • Raymond James & Associates's Atara Biotherapeutics position peaked at $1.09M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.